Effectiveness and Safety of Duloxetine in Women Experiencing Urinary Leakage Due to Physical Stress...
Urinary IncontinenceStressThe purpose of the study is to evaluate the effectiveness of duloxetine in reducing urinary incontinence(leakage of urine)occurrences in women due to physical stress and leakage that occurs during a strong need(urge) to urinate.
Open Label Phase III Duloxetine Study for Stress Urinary Incontinence
Urinary Incontinence StressThe purpose of this study is to monitor the long term safety of duloxetine in the treatment of stress urinary incontinence.
Efficacy and Safety of Duloxetine, Placebo and Pelvic Floor Muscle Training in Subjects With Stress...
Urinary Stress IncontinenceThe study is a comparison of the efficacy and safety of duloxetine and pelvic floor muscle training with that of placebo in patients with moderate to severe stress urinary incontinence
To Evaluate the Safety of Duloxetine in Patients With Stress Urinary Incontinence
Stress Urinary IncontinenceThe patients are being followed in this study to determine the safety of taking the medication Duloxetine for a long period of time. The patients participating in this study suffer from Stress Urinary Incontinence.
Materiovigilance After Urinary Incontinence or Prolapse Surgery
Pelvic Organ ProlapseRectal Prolapse1 moreObservatory of Materiovigilance After Surgery of Urinary Incontinence or Prolapse in Women Implantable medical devices (meshes) used in pelvic organ prolapse surgery (genital prolapse, rectal prolapse), or incontinence surgery may be source of severe complications.
The Development of De-novo Stress Urinary Incontinence After Stage II-III Pelvic Organ Prolapse...
Pelvic Organ ProlapseSurgery for Stage II-III Pelvic organ prolapse
Preliminary Performance Study of the New TIPI Device in the Prevention of Stress Urinary Incontinence...
Stress Urinary IncontinenceStress urinary incontinence (SUI) is most prevalent among women. SUI is characterized by loss of urine from increased abdominal pressures caused by coughing, laughing, sneezing, running, lifting or walking. SUI cause women to avoid routine physical activities, thus detracting significantly from their quality of life. The purpose of this study is to evaluate the performance of new designs of the TIPI device, a conservative, disposable, treatment for temporary management of SUI.
Evaluation Of The Ability Of Fesoterodine To Increase Urethral Pressure In Stress Urinary Incontinence...
Stress Urinary IncontinenceThe hypothesis under evaluation is that fesotorodine may provide clinical benefit in the treatment of the condition of stress urinary incontinence
TVT-SECUR as an Office-based Procedure
Urinary IncontinenceStress Urinary IncontinenceThis is a pilot study to assess the feasibility and success of performing the TVT-Secur in the office setting. Endpoints would be success, complications, and patient and physician acceptance of the procedure. Success would be assessed by validated questionnaires. This is a prospective single arm study of 50 patients who will have the TVT-Secur procedure done in the office under local anesthesia. They will be followed for a period of 3 years.
Tension Free Vaginal Tape (TVT) Versus the Miniarc Sling
Urodynamic Stress IncontinenceThe aim of this study is to assess whether the Miniarc suburethral sling is equivalent to the TVT in the treatment of women with urodynamic stress incontinence (USI). If equivalence is proven, the advantages to women with USI will be potentially significant since the Miniarc may be carried out as an office based procedure, negating the need for an anaesthetic and hospital admission. The investigators null hypothesis is that there is no difference in subjective or objective outcome between the TVT and the Miniarc in the treatment of USI. Eligible women will be initially assessed with a full history and examination, King's Health Questionnaire and twin channel subtraction cystometry. They will be randomised (using a series of numbered opaque envelopes) to undergo either the TVT or Miniarc. Follow up will be at 6 weeks, with a subjective outcome measure and at 6 months with a repeat subjective assessment and repeat twin channel cystometry.